Please login to the form below

Not currently logged in
Email:
Password:

Patent loss

This page shows the latest Patent loss news and features for those working in and with pharma, biotech and healthcare.

Amarin shares tumble following Vascepa patent loss

Amarin shares tumble following Vascepa patent loss

The patent ruling only applies to Vascepa’s US patent exclusivity, with Amarin clarifying that its patents elsewhere in the world still stand.

Latest news

More from news
Approximately 1 fully matching, plus 152 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    Pfizer is coming off ten years of patent expiries, plus a pipeline that hasn’t yielded as many new products as hoped in that period, and that prompted Bourla to implement ... He has already taken some pretty seismic decisions, such as axing R&D in

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    There’s also some urgency for the transaction to go quickly and smoothly as AbbVie prepares for the loss of patent protection for $20bn immunology drug Humira (adalimumab) in the US ... AZ’s new growth phase comes after a six-year sales slump thanks

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... non‐biologic product post‐patent loss, highlighting the benefits of biologics

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    years for AZ to return to top-line growth after the patent loss of blockbuster brands such as Nexium and Crestor.

  • Pharma deals during February 2014 Pharma deals during February 2014

    been much analysis as to why Actavis paid as much as it did when Forest seemingly could have been bought much more cheaply, given the loss of patent protection on ... s best selling depression drug Lexapro and another patent cliff looming for Nameda, its

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...

Infographics